Roberto Olivarez
Optometrist · McAllen, TXNPI 1144395302
Payments from drug & device makers
Across 419 payments — averaging $46.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$8K
- Biotissue Holdings Inc.$2K
- Bausch & Lomb Americas Inc.$1K
- Coopervision Inc.$1K
- Oyster Point Pharma, Inc.$930
- AbbVie$922
- plus $5K from 18 others
What the payments were for
- Consulting fees$1,8059%
- Speaking & faculty fees$1,0005%
- Travel & lodging$3,18416%
- Food & beverage$13,59369%
- Gifts$190%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 122 | $8,063 |
| Biotissue Holdings Inc. | 22 | $2,209 |
| Bausch & Lomb Americas Inc. | 53 | $1,496 |
| Coopervision Inc. | 38 | $1,238 |
| Oyster Point Pharma, Inc. | 36 | $930 |
| AbbVie(2 entities) | 25 | $922 |
| Lumenis BE Inc | 1 | $849 |
| Novartis | 49 | $720 |
| Tarsus Pharmaceuticals, Inc. | 15 | $517 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $504 |
| Aerie Pharmaceuticals, Inc. | 6 | $468 |
| Sun Pharmaceutical Industries Inc. | 9 | $424 |
| Dompe US, Inc. | 4 | $276 |
| Shire North American Group Inc | 9 | $206 |
| Sight Sciences, Inc. | 4 | $174 |
| Harrow Eye, LLC | 1 | $148 |
| LKC Technologies, Inc. | 1 | $137 |
| Rxsight Inc | 1 | $103 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $95 |
| Eyevance Pharmaceuticals LLC | 2 | $43 |
| ABB Con-cise Optical Group LLC | 2 | $41 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $17 |
| Optos, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$3,152
- Precision 1$1,344
- M22$849
- DAILIES TOTAL1$761
- XIIDRA$589
- AIR OPTIX$500
- MIEBO$450
- Rhopressa$342
- Rocklatan$342
- CEQUA$329
- Oxervate$250
- LUMIGAN$246
- XDEMVY$230
- MiSight Contact Lens$222
- VYZULTA$217
- VEVYE$148
- RESTASIS$125
- TOTAL30$124
- TearCare SmartLid$118
- TEARCARE(TM) (2.2) SYSTEM KIT$118
How this compares
$19,618 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 37 | $66,930 |
| XiidraLifitegrast | 24 | $36,994 |
| XdemvyLotilaner | 14 | $25,803 |
| TyrvayaVarenicline Tartrate | 11 | $14,675 |
| RestasisCyclosporine | 14 | $12,740 |
| EysuvisLoteprednol Etabonate | 13 | $6,123 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $4,507 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $3,089 |
| Latanoprost | 93 | $1,457 |
| Timolol Maleate | 20 | $337 |
| Amoxicillin | 26 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $1,496 | $103,92461 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $517 | $25,80314 claims |
| AbbVieRestasis, Combigan | $922 | $15,82929 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $930 | $14,67511 claims |
| AlconSimbrinza | $8,063 | $4,50714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in McAllen
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
- Luis RojasMcKinney$309K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.